
PSTV Stock Forecast & Price Target
PSTV Analyst Ratings
Bulls say
Plus Therapeutics is a clinical-stage pharmaceutical company with potential treatments for cancer and rare diseases, and their main programs targeting recurrent glioblastoma and leptomeningeal metastases. They have shown solid progress on clinical trials, with their lead drug RNL being evaluated in a Phase 2 clinical trial and their diagnostic tool CNSide already launched. With major grant wins and economic value propositions supporting the commercial rollout of CNSide, the company has significant potential for growth and success in the market.
Bears say
Plus Therapeutics is facing challenges in securing major contracts for its CNSide product, with only three agreements announced so far. Despite maintaining their revenue estimates for 2026, the company is expecting a decrease in EPS due to adjusting estimates for Q4. Furthermore, the company's recent Q4 2025 results were lower than both their own and consensus estimates, raising concerns about their financial performance.
This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
PSTV Analyst Forecast & Price Prediction
Start investing in PSTV
Order type
Buy in
Order amount
Est. shares
0 shares